Immunome, Inc. (IMNM)

Price$18.58

Value ScoreF

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-7.06%

Price vs S&P 500 (4W)-17.19%

VGM Score27.68

Market Capitalization$2.10B

All Metrics

Book Value / Share (Quarterly)$5.20

P/TBV (Annual)20.53x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.90

Price vs S&P 500 (YTD)-21.66%

Net Profit Margin (TTM)-1687.08%

EPS (TTM)$-2.36

10-Day Avg Trading Volume1.26M

EPS Excl Extra (TTM)$-2.36

EPS (Annual)$-2.43

ROI (Annual)-33.48%

Cash / Share (Quarterly)$5.15

ROA (Last FY)-31.09%

Revenue Growth TTM (YoY)-63.29%

EBITD / Share (TTM)$-2.47

ROE (5Y Avg)-111.44%

Operating Margin (TTM)-1784.14%

Cash Flow / Share (Annual)$-1.83

P/B Ratio3.57x

P/B Ratio (Quarterly)4.20x

Net Income / Employee (Annual)$-1,815,300

EV / Revenue (TTM)120.86x

Net Interest Coverage (TTM)-2470.00x

ROA (TTM)-47.32%

EPS Incl Extra (Annual)$-2.43

Current Ratio (Annual)14.69x

Quick Ratio (Quarterly)21.26x

3-Month Avg Trading Volume1.19M

52-Week Price Return103.73%

Revenue / Employee (TTM)$34,300

Tangible BV / Share (Quarterly)$0.50

P/S Ratio (Annual)303.15x

Asset Turnover (Annual)0.01x

52-Week High$27.65

EPS Excl Extra (Annual)$-2.43

CapEx CAGR (5Y)93.32%

26-Week Price Return0.87%

Quick Ratio (Annual)14.53x

13-Week Price Return-11.31%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)21.68x

Enterprise Value$1.52B

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)7.59%

Revenue / Employee (Annual)$59,300

Pretax Margin (Annual)-3059.99%

Cash / Share (Annual)$5.78

3-Month Return Std Dev57.15%

Net Income / Employee (TTM)$-1,919,600

ROE (Last FY)-33.48%

Net Interest Coverage (Annual)-784.00x

EPS Basic Excl Extra (Annual)$-2.43

P/FCF (TTM)128.80x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.36

ROI (TTM)-51.15%

P/S Ratio (TTM)167.15x

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$1.37

Price vs S&P 500 (52W)79.36%

Year-to-Date Return-13.50%

5-Day Price Return-10.59%

EPS Normalized (Annual)$-2.43

ROA (5Y Avg)-84.20%

Net Profit Margin (Annual)-3059.99%

Month-to-Date Return-14.89%

Cash Flow / Share (TTM)$-1.77

EBITD / Share (Annual)$-2.54

Operating Margin (Annual)-3228.83%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-111.44%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.36

P/TBV (Quarterly)56.26x

P/B Ratio (Annual)3.74x

Pretax Margin (TTM)-1687.08%

Book Value / Share (Annual)$5.61

Price vs S&P 500 (13W)-19.57%

Beta2.11x

Revenue / Share (TTM)$0.04

ROE (TTM)-51.15%

52-Week Low$7.96

vGradeF

gGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.48est. -0.57

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.26

4.25

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
IMNMImmunome, Inc.	F	F	C	$18.58
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Immunome Inc is a targeted oncology company advancing antibody-drug conjugates and radioligand therapies. Its lead program, varegacestat, demonstrated positive Phase 3 results in desmoid tumors, with additional programs including the Phase 1-stage ROR1 ADC IM-1021 and IND-cleared FAP-targeted radioligand IM-3050. The company maintains a preclinical portfolio of solid tumor ADCs.